Literature DB >> 23070775

Lipopeptide delivery of siRNA to the central nervous system.

Mark D Zabel1.   

Abstract

RNA interference is a relatively new tool used to silence specific genes in diverse biological systems. The development of this promising new technique for research and therapeutic use in studying and treating neurological diseases has been hampered by the lack of an efficient way to deliver siRNA transvascularly across the blood-brain barrier (BBB) to the central nervous system (CNS). Here we describe a method for delivering siRNA to the CNS by complexing it to a peptide that acts as a neuronal address by binding to acetylcholine receptors (AchRs). Adding cationic liposomes to the complex protects it from serum nucleases and proteases en route. When injected intravenously, these liposome-siRNA-peptide complexes resist serum degradation, effectively cross the BBB, and deliver siRNA to AchR-expressing cells to suppress protein expression in the CNS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23070775      PMCID: PMC6043354          DOI: 10.1007/978-1-62703-140-0_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  47 in total

Review 1.  Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development.

Authors:  K J Harrington; C R Lewanski; J S Stewart
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

Review 2.  Lentiviral vectors in clinical trials: Current status.

Authors:  Jenice D'Costa; S Gary Mansfield; Laurent M Humeau
Journal:  Curr Opin Mol Ther       Date:  2009-10

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

5.  Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.

Authors:  Miriam Rothdiener; Dafne Müller; Patricia Garrido Castro; Anja Scholz; Michael Schwemmlein; Georg Fey; Olaf Heidenreich; Roland E Kontermann
Journal:  J Control Release       Date:  2010-02-22       Impact factor: 9.776

6.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

Authors:  M R Ranson; J Carmichael; K O'Byrne; S Stewart; D Smith; A Howell
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

7.  Advances in Systemic siRNA Delivery.

Authors:  Qixin Leng; Martin C Woodle; Patrick Y Lu; A James Mixson
Journal:  Drugs Future       Date:  2009-09       Impact factor: 0.148

Review 8.  Delivery of small-interfering RNA (siRNA) to the brain.

Authors:  Saroj P Mathupala
Journal:  Expert Opin Ther Pat       Date:  2009-02       Impact factor: 6.674

9.  Is the acetylcholine receptor a rabies virus receptor?

Authors:  T L Lentz; T G Burrage; A L Smith; J Crick; G H Tignor
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

10.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  2 in total

1.  Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.

Authors:  Jack Wuyang Jin; Xuelai Fan; Esther Del Cid-Pellitero; Xing-Xing Liu; Limin Zhou; Chunfang Dai; Ebrima Gibbs; Wenting He; Hongjie Li; Xiaobin Wu; Austin Hill; Blair R Leavitt; Neil Cashman; Lidong Liu; Jie Lu; Thomas M Durcan; Zhifang Dong; Edward A Fon; Yu Tian Wang
Journal:  Commun Biol       Date:  2021-02-19

Review 2.  Lipid-based nanoparticles and RNA as innovative neuro-therapeutics.

Authors:  Maria Tsakiri; Cristina Zivko; Costas Demetzos; Vasiliki Mahairaki
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.